Warm-toned photograph of a stethoscope resting on a wooden desk beside medical charts, conveying a serious healthcare setting

A national public affairs campaign launched by the American College of Cardiology in December 2009 to oppose Medicare physician fee schedule cuts affecting cardiology patients and practices.

About the Campaign

The Campaign for Patient Access was launched by the American College of Cardiology in December 2009 as a national effort to reverse Medicare physician fee schedule cuts that threatened cardiovascular care. The site provided background on the issue, the ACC's legislative and legal response, resources for patients and practices, a newsroom tracking coverage across the country, and ways for supporters to share their stories and support the campaign.

From the Newsroom

Capitol building dome against a pale sky, conveying federal policy and legislative action
April 30, 2010

Medicare Meltdown: Access to Health Care in "Critical Condition"

A press release warning that cardiology access was in critical condition due to Medicare payment cuts.

Read more
Gavel on a dark wooden bench in a courtroom setting, suggesting legal proceedings
December 29, 2009

Cardiology Takes Legal Action Against Medicare

The ACC filed suit against HHS Secretary Kathleen Sebelius over the 2010 Physician Fee Schedule.

Read more
A stack of newspapers with a muted gray and off-white palette, suggesting breaking health policy news
January 12, 2010

ACC Statement on Health Care Reform

The ACC used the State of the Union address to highlight the need to reverse the Medicare cuts.

Read more
A wide shot of a diverse group of healthcare professionals and advocates gathered around a conference table, deep in discussion
April 12, 2010

Medicare Patients and Physicians Join Petition Drive

Patients and physicians in Washington, DC joined a petition drive calling on Congress for Medicare reform.

Read more

Reimbursement Cuts Put Inherited Heart Condition Testing at Risk

Genetic testing has quietly become ordinary cardiology work. A blood draw, a sample in the post, and a report that may confirm hypertrophic cardiomyopathy, long QT syndrome, or a Marfan variant — and with it, a decision about beta-blockers, about whether a teenager keeps playing competitive netball, about whether three siblings need screening of their own. What once took a decade of family history and intuition now arrives in weeks. The technology is affordable; the open question is whether the payment system still rewards anyone for finding it.

That question is being answered badly in the United States. The calendar 2026 Medicare Physician Fee Schedule, released in October 2025, cut the conversion factor that sets payment for thousands of services by roughly six per cent, with sharper reductions for many office-based and ancillary codes and small increases reserved for primary care and behavioural health. Genetic and genomic testing sits in the middle of that squeeze: the machine cost of sequencing has collapsed, while the human hours of variant interpretation, phenotype matching, and report writing have not. Providers are beginning to ration the work, and patients with inherited heart conditions absorb it.

How Fee Schedule Cuts Reach the Laboratory

The transmission belt runs through coding. Cardiology practices bill genomic panels under CPT codes such as 81420 and 81428, external rhythm monitoring for QT assessment under 93224, and remote physiologic monitoring for arrhythmia surveillance under the 99453-99457 family. When the conversion factor falls, every dollar billed buys a smaller payment from the Medicare Administrative Contractor that processes the claim. Laboratory work is more exposed than most, because the fee schedule for clinical diagnostic laboratory services is benchmarked to reference laboratory rates and then negotiated separately with each MAC.

Downstream, commercial insurers price their own schedules off Medicare benchmarks, so a public sector reduction is quietly repriced in the private market. Practices that cannot make the economics work reduce the menu. Panels get bundled into fewer genes. Cascade testing of asymptomatic relatives gets postponed. Reports get written on a template, with less time spent on the family that generated them.

Service area Representative code Payment direction Likely effect on inherited heart condition care
Cardiovascular gene panels 81420, 81428 Reduced Fewer panels offered, more out-of-pocket testing
Proband and cascade testing 81428, 81432 Reduced Relatives screened late, or not at all
QT assessment by rhythm monitor 93224 Reduced Longer waits for ambulatory monitoring
Remote physiologic monitoring 99453-99457 Partly protected Partial offset, only where a device is already in place
Genetic counselling visits 90832, 99204 family Reduced Shorter, less specialised counselling sessions

Why Inherited Heart Conditions Are Different

Clinical genetics has a feature most medical services lack: the first test is only half the job. A pathogenic variant found in a proband becomes a screening list for parents, siblings, and children, and each of those tests carries its own cost, its own referral, and its own chance of being declined. Insurers routinely cover the proband and treat relatives as an optional extra, even though the clinical logic is identical and the cost of a miss is a sudden cardiac arrest in a young person.

Timing does the rest of the work. A diagnosis of long QT syndrome changes medication the same week, not next year. A negative result in a family with a known familial mutation may release a young athlete back onto the field, which is exactly the population sudden cardiac death takes. Practices feel this pressure hardest in the months after a bereavement, when a family arrives wanting answers about a sibling who died without warning, and the answer sits in a genetic report nobody has budgeted for.

There is also a strategic dimension rarely said out loud. Cardiology's revenue mix has always leaned on imaging, stress testing, and procedures, all under pressure from fee schedule reductions, site-of-service consolidation, and prior authorisation. Genetics and precision cardiology are among the few areas still growing, which makes them attractive targets for payers cutting where volumes rise. The result is a perverse allocation: the service with the highest information value per dollar is the one most likely to be squeezed.

What This Looks Like in Australia

Australia feels the same pressures through different plumbing. The Medicare Benefits Schedule lists cardiovascular genetic testing only narrowly — items exist for certain familial conditions, but broad panels, exome-scale testing, and family cascade screening are frequently unfunded, so families either pay privately or wait for a public hospital budget to absorb the cost. That wait shows up in cardiology clinics in Melbourne, Sydney, Brisbane, and Perth, where category 2 outpatient waits have stretched under years of workforce shortage and elective funding that treats tests without a procedure as lower priority.

The referral pathway is where local policy bites hardest. Because MBS coverage for genetics is thin, most cardiovascular genetic testing arrives through a general practice referral, and general practices are themselves under financial strain: reduced bulk-billing incentives from January 2025 left many charging gaps for standard consultations. A patient who balks at a $60 gap is unlikely to also fund a panel costing about A$1,800 plus travel to a genetics service across town. Telehealth items introduced during the pandemic have genuinely helped — genetic counselling by video from a regional centre is now routine — but they cannot substitute for a test nobody will fund.

The people keeping this work alive are a small professional community. Cardiologists at centres such as Baker IDI in Melbourne, Garvan in Sydney, and the adult congenital services in Perth and Brisbane run counselling clinics with minimal staff, supported by families who have lost someone to an inherited arrhythmia. Heart Foundation Australia and Cardiac Australia press for recognition; individual clinicians quietly absorb the administrative cost of cascade screening no one has claimed.

Australians tend to talk about health access in plain terms — the fair go, a decent system for the bloke in the middle, no gaps. When a mother in Bendigo or a father in Townsville is told their son's cardiomyopathy needs a genetic panel and the cost sits outside the public system, the complaint is rarely about laboratory science. It is about who pays, and whether the system still works the way it was sold to us.

Lessons From Other Policy Debates

The recurring lesson of American health politics is that cuts framed as corrections land on the people with the least political voice, while the argument for restoring them gets made in terms of access rather than science. The same pattern shows up far from medicine. The debate over California's three strikes law turns on a question Americans know well: whether a punitive framework should survive because it was popular, or because the evidence says it works. Each of those arguments rhymes with the argument over Medicare's conversion factor, where the popular framing is cost control and the evidence concerns what happens to the last five per cent of patients.

Australian institutions offer a cleaner route for the same conversation. Rather than lobbying a committee that meets only once a crisis is already visible, patients and clinicians can write to their federal member, put a case to a Senate committee inquiry, and use the public submissions process that sitting committees must consider. A submission with a family story attached travels further than a technical brief, which is why advocacy organisations behind the US campaign built their effort around patient and practice narratives rather than actuarial modelling.

Speak Up for Access

For patients, the most useful thing is a record. Keep the pathology report, the letter from the insurer or public service declining the test, the dates, and the names of the clinicians who asked for it. That record becomes the spine of a submission to a member of parliament, a complaint to a health insurer, or an application for public funding, and it takes an hour to assemble while the details are fresh.

For clinicians, log what you are not doing: how many cascade tests were deferred because the family could not pay, how many reports were outsourced, how many cardiology reviews were delayed. Practices can add their own data to the campaign materials, and the aggregate is what moves a fee schedule conversation. The resource hub run by the Campaign for Patient Access collects patient stories, practice resources, and the legal and legislative background, so a few minutes there replaces a week of trying to find your own way into the process.

None of this waits for a rule to be final. Fee schedules are set ahead of the year they apply, advocacy windows open before decisions are made, and a story told now can still shape the schedule that follows. Patients, families, and practices across Australia can add their voices while the decisions remain reversible.

A close-up of a handwritten letter on paper beside a pen, warm natural light, soft cream and muted gray tones

Share Your Story

Tell us how Medicare cuts affected access to cardiovascular care. Stories could be reviewed and submitted to local news outlets as part of the campaign's outreach.